Inhibiting the ATM pathway with concomitant treatment of TMZ may act synergistically in a prolonged manner even during post-treatment, thereby serving as a more severe treatment strategy to kill or suppress the proliferation of e.g., cancer progenitor cells that are more resistant to chemotherapy. This evidence concerns the gene ATM and cancer.